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Background: The Comprehensive Geriatric Assessment (CGA) is an analytical tool increasingly implemented in
clinical practice. Breast cancer is primarily a disease of older people; however, most evidence-based research is
aimed at younger patients.
Methods: A systematic review of literature was carried out to assess the use of CGA in older breast cancer patients
for clinical decision making. The PubMed, Embase and Cochrane databases were searched.
Results: A total of nine useful full text article results were found. Only five of these were exclusively concerned with
early breast cancer; thus, studies involving a variety of cancer types, stages and treatments were accepted, as long
as they included early breast cancer.The results comprised a series of low sources of evidence. However, all results
shared a common theme: the CGA has a use in determining patient suitability for different types of cancer
treatment and subsequently maximizing the patient’s quality of life.
Conclusions: There is not yet sufficient high level evidence to instate CGA guidelines as a mandatory practice in
the management of breast cancer, due to the heterogeneity of available studies. More studies need to be
conducted to cement current work on the benefits of the CGA. An area of particular interest is with regard to
treatment options, especially surgery and chemotherapy, and identifying patients who may be suitable for these
treatments.
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The Comprehensive Geriatric Assessment (CGA) is a
multidisciplinary management tool aimed at determining
an older person’s medical, psychological and functional
capability [1].
Current evidence regarding breast cancer is mainly ap-
propriate to younger patients (≤65 years) as older
patients are often excluded from clinical trials [2,3].
There is a need for further research focusing solely on
older patients, or by stratification of patients by age, to
allow for accurate treatment guidelines.* Correspondence: kl.cheung@nottingham.ac.uk
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reproduction in any medium, provided the orDisadvantages of CGA include additional time of im-
plementation and limited consensus regarding method-
ology, evaluation and utilization [3]. Comprehensive
geriatric assessment generally consists of a few major
components, including: medical assessment of current
diagnoses, medications and nutritional status; assessment
of physical function; psychological evaluation to deter-
mine patient mentality and mood; and social and envir-
onmental assessments [1].
Currently, CGA is not used routinely in breast can-
cer patients worldwide; however, three main areas
where CGA could potentially be implemented include
the following.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Since age alone may not be an accurate predictor of
treatment outcome [4], CGA could assist in distinguish-
ing between those who should be given more invasive
treatments after taking into consideration tumor type
and different treatment options.Assessing appropriateness of treatment
Greater comorbidity increases risk of death from causes
other than breast cancer [5,6]. Consequently, older
patients may feel the benefit of surgery for breast cancer
is not worthwhile, though with modern surgical and
improved anesthetic techniques, fewer patients are
now deemed unfit for surgery. On the other hand,
there may be situations where non-operative therapies
(for example, primary endocrine therapy) or even no
treatment may be considered preferable due to a
number of factors, some of which are related to frailty
and/or co-morbidities.Identifying deficits in health
There is the need for identification of patients with con-
founding health problems, social needs or other issues
that may have otherwise remained undetected [7], which
could impact on the management of the patient’s cancer.
Assessment in these areas allows establishment of tar-
geted treatment plan specific to the individual patient,
leading to potential benefits, such as optimization of
medical treatment; improved diagnostic accuracy and
prognosis; maintained function; and improved quality of
life (QOL) [8-11].Figure 1 Selection of articles for review.The aim of this systematic literature review was to
analyze current evidence regarding CGA in early breast
cancer and highlight possible areas for further research.Methods
Three online databases were searched for relevant litera-
ture, including full-text articles and abstracts. These were
PubMed, Embase and the Cochrane Library, which cover
most clinical studies with high level evidence. The fol-
lowing key words were used: comprehensive geriatric
assessment, breast cancer, primary, operable. Studies pub-
lished in English in the past 10 years (January 2001 to
September 2011, as far as access was allowed) were
included. Studies were excluded if: a form of geriatric as-
sessment was not used in the methodology; there was no
relation to cancer; or no early breast cancer patients were
included (Figure 1).
The search limits yielded nine full-text articles
(Table 1).
The following aspects of each study were examined:
date of publication; context of result; level of evidence
the study presented (Level); number of participants (N);
lower age cut-off of participants; type of cancer the parti-
cipants had; stage of cancer; uniqueness of study; overall
findings.
Level of evidence was assessed using the system pro-
posed by Harbour and Miller [21], where evidence is
graded in terms of ‘quantity, quality, consistency, applic-
ability, generalizability and impact.’ This system has been
adopted by the National Institute of Clinical Excellence
[22]: ‘Grading evidence and recommendations for public
health interventions’, considering factors including evidence
Table 1 Results from full-text articles
Date Study Context L N Age Type Stage Uniqueness of study Findings
Jan 2004 Extermann M
et al. [12]
Single center pilot study
assessing role of CGA in
oncological treatment.
3 15 ≥70 Breast 55% Stage I, 45%
Stage II
QOL was measured by the
Functional Assessment of Cancer
Treatment-Breast tool. Functional
status was assessed by ADL, IADL,
ECOG-PS, GDS, MNA, Charlson
Comorbidity Index, CIRS-G.
CGA with follow-up can extend
quality of life in these patients from
treatment and prognostic aspects.
Nov 2005 Hurria A et al. [13] Feasibility study concerning
a cancer-specific CGA.
3 43 ≥65 25% breast, 18%
CRC, 38% lung,
20% lymphoma
5% Stage 1, 10%
Stage II, 18% Stage III,
68% Stage IV
Specifies use of ADL, IADL, KPS,
Timed Up and Go, BOMC, HADS,
MOS, Seeman and Berkman Social
Ties, BMI, % unintentional weight
loss in the last six months in a CGA
that is specific for cancer. Specifies
ethnicity of participants as 90%
white, 10% black.
The cancer-specific CGA can be
completed by the majority of
patients to provide reliable and valid
results.
Dec 2006 Pope, D et al. [14] Study of Geriatric Assessment
in older patients with
operable cancer.
3 460 >70 216 breast, 146
GIT, 71 GUT, 27
other
For breast cancer:
48% Stage 1, 39.3%
Stage 2, 12.7% Stage
3.
Specified use of PACE, an advanced
form of CGA using BFI, ECOG-PS,
IADL, GDS, MMSE, ASA and SIC.
Geriatric Assessments can be a useful
tool in evaluating fitness for surgery
in the older cancer patient.
Jan 2008 Albrand, G and
Terret, C [15]
Single-center review of
assessment of breast cancer
in the older.
3 76 >70 Breast Primary Specific for breast cancer. Specifies
use of CIRS-G score as part of CGA.
CGA should be performed before
any treatment decisions are made.
More trials need to be conducted
involving older patients, to
determine efficacy of chemotherapy
in older breast cancer patients.
March 2010 Gironés, R et al.
[16]
Single-center experience of
use of CGA for breast cancer
patients.
3 91 >70 Breast 26% Stage I, 58%
Stage II, 16% Stage III
Specific for breast cancer, specifying
use of ADL, IADL, ECOG PS, GDS,
Charlson comorbidity index, BMI,
Balducci criteria for frailty in CGA.
Function and independence in older
breast cancer patients with co-
morbidities can be preserved by use
of CGA. CGA is often too time
consuming to be practically assessed
in an oncology setting.
Jul 2010 Molina- Garrido,
M and Guillén-
Ponce, C [17]
Single center comparison of
two frailty screening tools
and CGA.
3 41 ≥65 Breast 53.7% Stage I, 41.5%
Stage II, 2.4% Stage III,
2.4% Stage IV
Specific for breast cancer. Specifies
use of ADL, IADL, Charlson
comorbidity index, Pfeiffer test for
cognition and NSI.
Patients who had a score indicative
of frailty had scores in CGA
suggesting poorer physical function,
malnutrition and cognition.




of adjuvant chemotherapy to
older breast cancer patients
3 192 >70 Breast Primary Specific for primary breast cancer
only. Specifies use of ADL, IADL,
ECOG PS, GDS, BMI, MNA, CIRS-G.
Some components of CGA may be
able to determine its use in
predictability of chemotherapy use.
Jul 2011 Lazarovici, C et al.
[19]
Single center investigation
into what components of
CGA correlate to need for
geriatric referral within older
cancer patients





Specifies use of ADL, IADL, MMSE,
BMI, CIRS-G
Patients who had CGA before they
had made their cancer treatment
decision were more likely to receive
an altered treatment plan.
Aug 2011 Hurria, A et al. [20] A multicenter trial to assess
use of CGA in determining
3 700 ≥65 Lung (29%), GI
(27%),
gynaecological
5% Stage I, 12% Stage
II, 22% Stage III, 61%
Stage IV
Same CGA format used in previous
study by Hurria et al. [13]
Some components of the CGA can
be used to assess potential toxicity




























ADL, Activities of Daily Living; ASA, American Society of Anesthesiologists grade; BFI, Brief Fatigue Inventory; BMI, Body Mass Index; BOMC, Blessed-Orientation Memory Concentration test; CGA, Comprehensive Geriatric
Assessment; CIRS-G, Cumulative Illness Rating Scale – Geriatrics; CRC, Colorectal cancer; ECOG-PS, Eastern Cooperative Oncology Group Performance Status Scale; GDS, Geriatric Depression Scale; GIT, Gastro-intestinal
Tract; GUM, Genito-urinary Tract; HADS, Hospital Anxiety and Depression Scale; HHC, Home Health Care; IADL, Instrumental Activities of Daily Living; KPS, Karnofsky Performance Status; L, Level of evidence; MMSE, Mini-
mental state examination; MNA, Mini Nutritional Assessment; MOS, Medical Outcomes Study; N, Number of patients; NCI, National Cancer Institute; NIA, National Institute on Aging; NSI, Nutrition Screening Initiative;



















Parks et al. World Journal of Surgical Oncology 2012, 10:88 Page 5 of 9
http://www.wjso.com/content/10/1/88of efficacy, cost effectiveness, research design, relevance to
the UK population and consistency.
Results
Nine full-text articles met our search criteria and all
graded Level 3 for quality of evidence.
Despite the aim of this review to evaluate CGA in early
operable breast cancer, we found a minimal number of
studies being this specific, so all studies which contained
any number of early breast cancer patients are discussed.
1. A pilot study by Extermann et al. [12], recruited
patients from a single center aged ≥70 years with stage I
or II breast cancer, after surgery. Baseline assessment
was carried out and CGA completed on follow-up at
three andsix months for 15 patients.
After CGA, cancer treatment was adjusted in four par-
ticipants (36%); adjuvant endocrine therapy was selected
in two patients and adjuvant chemotherapy in one pa-
tient. No information is available on the fourth patient.
In addition, CGA addressed problems indirectly impact-
ing on treatment, in a further six patients (55%), for ex-
ample, patient cognition, social support and contra-
indicating medications. These problems were effectively
resolved.
This study is unique in using the Functional Assess-
ment of Cancer Treatment-Breast (FACT-B) instrument
to measure QOL, validated by Extermann et al. [12].
Measures used in other similar studies (Table 1) are also
incorporated, allowing comparisons to be made.
Due to the small number of patients (N= 15), findings
from this study may not be comparable to all older pri-
mary breast cancer patients. Thus, more patients need to
be recruited from several centers, to verify findings.
2. A pilot study by Hurria et al. [13], consisting of 40
patients from two institutions, developed and measured
use of a cancer-specific geriatric assessment. Patients
aged ≥65 years, with breast, lung, colorectal carcinoma
or lymphoma, receiving chemotherapy and fluent in
English, were recruited. The CGA was carried out
after diagnosis with an aim to assess practicability of
administration.
Average completion time was 27 minutes (range 8 to
45 minutes) and 78% of the patients were able to
complete with no assistance. Approximately 90% of par-
ticipants were happy with the questionnaire length and
83% agreed it was easy to understand.
This study used a cancer-specific geriatric assessment
and has proven this is feasible. Of the 40 participants,
25% had breast cancer. The percentage of patients with
primary operable cancer is unknown; findings specific to
these patients cannot be determined.
The potential of applying this cancer-specific geriatric
assessment tool could be evaluated in a multicenter
study.3. A prospective study by Pope et al. [14] recruited 460
patients from centers in the UK, Italy, the Netherlands,
Belgium and Japan. Patients aged ≥70 years, undergoing
surgery for cancer were included. The majority of the
questionnaire was carried out prior to surgery with add-
itional measures dependent on the outcome of surgery,
completed afterwards.
Pope et al. [14] used an extended version of standard
CGA in their study: Pre-operative Assessment of Cancer
in the Older (PACE). In addition to the typical compo-
nents of CGA, PACE includes supplementary information
(Table 1) assessing overall functional performance.
As age of the patient increased, functional status
decreased. There was less comorbidity among breast
patients, when compared to those with gastro-intestinal
tumors (GIT) and genito-urinary tumors (GUT). This
could be due to the large number of patients with early
breast cancer included in this study, compared with GIT
and GUT, which consisted of patients with more evenly
distributed cancer stages; patients in later stages may ex-
perience more severe symptoms. Alternatively, this could
be explained by gender; greater comorbidity may exist in
the male rather than female population; breast cancer
patients are mainly female and GIT and GUT patients
largely male.
This is an excellent international study using a large
number of patients. All patients were receiving surgery,
however only 47% for breast cancer, 87.3% being primary
cases. Results appropriate to GIT and GIT cannot be dif-
ferentiated from breast tumors in this study.
4. Albrand and Terret [15] conducted a study in a sin-
gle unit for consecutive patients aged ≥70 years, present-
ing with primary breast cancer. The study employed
CGA to detect medical risks influencing cancer manage-
ment at follow up, for example, 17% of the cohort wwas
at risk of cognitive deterioration and 30% of depression.
These factors may impinge on the ability to make treat-
ment decisions, or increase susceptibility to adverse
treatment effects. These patients often present with good
performance status so may be inadequately prescribed
treatment based on this alone.
This study suggests CGA components related to func-
tion, mentality, nutrition and comorbidity assist in deter-
mining fitness for oncological treatments. Comorbidity
was measured using the Cumulative Index Rating Scale-
Geriatric (CIRS-G), which is only used by this study and
the study by Extermann et al. [12] and, therefore, these
studies cannot be directly compared to studies routinely
using the Charlson listing [23].
Similar studies need to be conducted on a larger scale in
multiple centers. Comparison of participants to matched
patients not receiving CGA would be useful to determine
if patient factors are acknowledged due to CGA or by in-
creasing awareness of the patient’s own disease status.
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[16] was conducted in a single center to assess comor-
bidity in breast cancer survivors. Participants were aged
≥70 years and had primary operable breast cancer. The
questionnaire was administered to 91 patients at follow-
up.
The study showed these older breast cancer survivors
were able to maintain function, but had high comorbid-
ity; consequently, long-term follow-ups are recom-
mended for cancer survivors. Gironés et al. [16] suggest
multidimensional geriatric assessment (MGA) ,which
considers the most relevant aspects of standard CGA
only; thus it is shorter.
Similarly, it would be useful if patients in this study
were matched to patients not receiving CGA.
6. A cross-sectional observational study by Molina-
Garrido and Guillen-Ponce [17] was concerned with the
feasibility of CGA application in early breast cancer
patients. Between 1 January 2007 and 31 December
2007, 41 consecutive patients aged ≥65 years were
recruited from a single center. All patients completed
the Barber Questionnaire (BQ), the Vulnerable Elderly
Survey (VES-13) and CGA, prior to receipt of
chemotherapy.
This CGA showed correlation to the briefer measures
of BQ and VES-13; patients who had a score indicative
of frailty on CGA were more likely to score a high level
of frailty on BQ and VES-13. Therefore, there is poten-
tial to develop a screening tool for administration of
CGA. This study suggests CGA should be implemented
when VES-13 score is <3 (maximum score 10, indicating
best possible outcome).
Of 41 patients, 56.1% had no daily medications and no
one had more than three daily medications, indicating a
possible level of good health in this cohort; it is expected
that older people will have greater comorbidity and thus
more daily medications. Furthermore, 78% of partici-
pants were married, which is a larger proportion relative
to others studies [13] and, hence, could be indicative of a
high level of social support in this cohort, which is not
always present in this age group. This sample may not be
representative of the whole population with early breast
cancer.
7. A retrospective study in a single center conducted
by Barthélémy et al. [18] attempted to assess the impact
that geriatric assessment, age and other prognostic fac-
tors had on treatment proposal of chemotherapy. All
patients with early breast cancer ≥70 years discussed by
the breast cancer tumor board at the University Hospital
of Strasbourg, between July 2006 and July 2009, were
considered. Patients were excluded if they presented with
either metastatic or a recurrence of breast cancer, as well
as those with a history of other cancer or previous
chemotherapy. All patients between age 70 and 79 withat least one comorbidity, as well as all patients aged
≥79 years, had been referred for CGA after discussion by
the breast cancer tumor board and thus there were a
total of 192 patient records available for analysis.
Prognostic factors, for example, estrogen and proges-
terone receptor status, and tumor stage were recorded.
The CGA included elements focusing on the domains of
comorbidity, mood, medication, social support, environ-
mental assessment, nutritional status and motor
function.
In this sample, 118 out of the 192 patients had at least
one or more risk factors which would ordinarily justify the
use of adjuvant chemotherapy. However, only 70 of these
patients (59%) were actually recommended adjuvant
chemotherapy after discussion with the multidisciplinary
team. The patients who did not receive chemotherapy des-
pite showing good indications, received adjuvant endo-
crine therapy as an alternative.
Barthélémy et al. [18] concluded that age was the only
independent factor associated with a lower rate of adju-
vant chemotherapy recommendation in this sample of
patients, especially after the age of 80 years. It is sug-
gested that CGA is useful in identifying patients who
may be at risk of adverse effects of chemotherapy, but
not necessarily identifying those who may benefit from
chemotherapy.
It is, however, worth noting that this study is largely
regarding administration of chemotherapy, which is
often not necessary for primary operable breast cancer
cases, rather than assessing these patients at diagnosis
aiming to formulate a management plan for primary
therapy.
8. Lazarovici et al. [19] carried out a retrospective re-
view of consecutive older patients refered to a single
oncogeriatric unit from October 2006 to April 2008. A
total of 65 patients were found and all had received
CGA. The review aimed to establish the difference be-
tween those patients who had undergone CGA before
treatment decision had been made (n = 35) and those
after treatment of cancer had started (n = 30).
The CGA was conducted by a single geriatrician with
oncological training. Where CGA was carried out before
a treatment decision was made, this was done on the
patient’s first visit to the geriatrician. The CGA assessed
functional status, cognition, mood, nutritional status and
comorbidity.
Recent weight loss of >10% was more frequent among
the group of patients who had geriatric assessment be-
fore cancer treatment decision had been made
(P= 0.031). These patients were subsequently later taking
fewer medications (P= 0.036) and more likely to received
adjusted cancer treatment (P= 0.051).
Lazarovici et al. [19] conclude that weight loss was the
main feature leading to geriatric referral. Conducting CGA
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more personalized individual treatment plan for these
patients.
A large proportion of patients in this study (60%) had
metastatic disease. Therefore, there might be some selec-
tion bias in this study, as patients with primary operable
breast cancer alone would have been less likely to be re-
ferred to the geriatrician under the criteria used in this
study, and thus would not have undergone CGA.
9. A further multicenter study by Hurria et al. [20]
aimed to identify risk factors for chemotherapy toxicity
in older breast cancer patients, assessing many diagnos-
tic and prognostic factors, including use of CGA. A total
of 500 patients aged ≥65 years attending an oncology
outpatient appointment at one of seven participating
centers, between November 2006 and November 2009,
were recruited to the study. All patients had a diagnosis
of cancer and were scheduled to receive adjuvant
chemotherapy.
Geriatric assessment was carried out before chemo-
therapy began. This study uses the same form of cancer-
specific CGA as previously mentioned in the earlier
study by Hurria et al. [13].
Regarding geriatric assessment, functional status, level
of social activity, poor hearing and assistance required to
take own medications, were important factors when con-
sidering chemotherapy toxicity.
This study was conducted on a large scale with the
aim to identify any general factors relevant to all cancer
types and stages with regards to toxicity from chemo-
therapy. The study did not look at whether there were
any additional or different factors based on particular
cancer types or stages.
Discussion
Due to the heterogeneity of our sample papers, it is diffi-
cult to draw comparisons relating to our original aim of
evaluating CGA use in early breast cancer.
The studies by Extermann et al. [12], Albrand and Terret
[15], Gironés et al. [16] Molina- Garrido and Guillén-
Ponce [17] and Barthélémy et al. [18] were solely con-
cerned with primary operable breast cancer and, thus,
have the greatest weight. However, these studies used a
small (N <200) sample size in their investigations com-
pared to the larger study by Pope et al. [14] (N=460). In
addition, these studies were conducted at a single-center
only, whereas Pope et al. [14] conducted an international
study, eliminating selection bias.
All studies used CGA to recognize comorbidities and
significant factors present in their patients, which could
potentially impact on treatment recommendation. The
studies by Extermann et al. [12], Hurria et al. [13] and
Gironés et al. [16] looked at CGA as a follow-up tool.
The aim of this was to establish toxicity or problemsarising from current treatment and determine necessary
treatment changes. A further aim of the studies by Hurria
et al. [13] and Molina-Garrido and Guillén-Ponce [17] was
to assess feasibility of including older patients in clinical
trials in general. The studies by Barthélémy et al. [18],
Hurria et al. [13] and Hurria et al. [20] were primarily
concerned with patients receiving chemotherapy and pos-
sibly toxicity arising from this.
All studies were Level 3 grade of evidence; conclusions
made may not be strong enough to require immediate
change to clinical practice [21,22].
Most of the studies used a similarly designed CGA, ex-
cluding the studies using cancer-specific CGA, by Hurria
et al. [13,20]. The standard components of a non-cancer-
specific CGA are not only used in cancer but in other
areas of geriatric medicine also. More studies need to be
conducted to determine whether a cancer-specific CGA
is more reliable and accurate than a general CGA.
A number of studies [12,13,15] imply CGA can be used
to determine treatment, especially regarding chemother-
apy. Chemotherapy is not widely used in older people
due to possible toxicity [24,25]. A CGA of the older can-
cer patient cannot only help establish fitness for surgery,
but also whether adjuvant chemotherapy may be a viable
option. The same reasoning applies to other cancer
treatments.
It appears that of CGA may be difficult to complete
due to impediments present in the older population in
general [26,27]. This may be indicative of the type of
treatment these patients should receive, or could simply
be a hindrance on completion of the CGA by the patient,
thus providing invalid data.
Due to the focused nature of this review, it appears
that a number of important articles may have been
excluded by our criteria, which are now discussed here.
Girre et al. [28] recruited 105 cancer patients aged
≥70 years for geriatric assessment. The majority of can-
cers were breast. Assessment of functional status, nutri-
tional status, mood, physical function, medication and
social and environmental support was made. Modifica-
tion of treatment decision due to geriatric assessment
was recorded in 39% of the patients. Factors associated
with modification of treatment plan included body mass
index and absence of depressive symptoms. Although no
information on the exact changes to treatment plan is
available, it is interesting that factors which may not be
considered without application of CGA, may affect treat-
ment decisions.
Also, an update of the study by Pope et al. [14] was writ-
ten by Audisio et al. [29]. In addition to the previous report,
they further analyzed 30-day morbidity and mortality and
length of hospital stay in breast, GIT and GUT patients. In
all groups, those experiencing complications were more
likely to have a poor outcome on the assessment,
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ing. Impairments of activities of daily living were important
for predicting length of hospital stay. Pope et al. [14] and
Audisio et al. [29] underline the impact of geriatric assess-
ment but also suggest that a cancer-specific geriatric assess-
ment for different subtypes of cancer should evolve.
Conclusions
From the literature, there is not yet enough evidence to rec-
ommend CGA in early breast cancer patients. Currently, lit-
erature suggests that CGA may be useful in regard to
treatment decision making in older cancer patients. This is
consistent with the clinical and pilot research experience of
the authors [30].
This literature review is hampered by lack of evidence
currently available concerning use of CGA in early breast
cancer patients. Analysis of some studies was inhibited
by the extent of information available, resulting in diffi-
cultly in drawing comparisons between studies. Evidence
so far suggests that CGA is an important factor in deter-
mining treatment and management of early breast can-
cer by identifying confounding health and personal
issues of the patient and their suitability for different
treatments, where this is possible. Case–control and co-
hort studies need to be completed to compare outcomes
of patients who receive CGA to those who do not.
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